2 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Withdrawn 2 |
Follow Urogenital Abnormalities: new trials by email Literature Review of Urogenital Abnormalities trials Research Report on Urogenital Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Androgen Reduction in Congenital Adrenal Hyperplasia Abiraterone acetate, Placebo, Hydrocortisone - Congenital Adrenal Hyperplasia | Phase 2 | Withdrawn | University of Texas Southwestern Medical Center | 2023-01-01 | 2023-02-01 | |
| Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO) Placebo, Tesomet - Hypothalamic Obesity | Phase 2 | Withdrawn | Saniona | 2021-11-11 | 2022-12-13 |
Adrenal Hyperplasia, Congenital (1) · Sexual Infantilism (1)
Congenital Abnormalities (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Disorders of Sex Development (2) · Endocrine System Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Gonadal Disorders (2) · Male Urogenital Diseases (2) · Urogenital Diseases (2) · Adrenal Gland Diseases (1) · Adrenogenital Syndrome (1) · Genetic Diseases, Inborn (1) · Gonadal Dysgenesis (1) · Hypogonadism (1)
Abiraterone Acetate (1) · Fludrocortisone (1) · Hydrocortisone (1) · Metoprolol (1) · Tesofensine (1)
Saniona (1) · University of Texas Southwestern Medical Center (1)
United States (2)
Perrin C White, MD (1) · Sophie Guillaume, MS (1)